

## The 2007 Dolph Adams Award and the state of the *Journal of Leukocyte Biology*

This is the 10th year that the Society of Leukocyte Biology has awarded authors cash prizes in honor of Dolph Adams. The \$1000 cash award recognizes the most highly-cited research paper and highly-cited review article published during the previous five years in the *Journal of Leukocyte Biology*. The prizes are awarded directly to the corresponding authors, who can decide how it will be distributed. The 2006 Dolph Adams Award winner for the most highly-cited research article was Benhur Lee, corresponding author of the manuscript “Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro” (*J. Leukoc. Biol.* 71, 445–457, 2002; 99 citations). The award winner for the most highly-cited review article was Bryan R. G. Williams, corresponding author of the manuscript “Functional classification of interferon-stimulated genes identified using microarrays” (*J. Leukoc. Biol.* 69, 912–920, 2001; 115 citations).

We are pleased to announce that the winner of the 2007 Dolph Adams Award for an original research paper is Jason Marshall, who is currently a Senior Scientist at Dynavax Technologies Corporation, Berkeley, California. The manuscript, “Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions” by Jason D. Marshall, Karen Fearon, Christi Abbate, Sandhya Subramanian, Priscilla Yee, Josh Gregorio, Robert L. Coffman, and Gary Van Nest. (*J. Leukoc. Biol.* 73, 781–792, 2003) has been cited 75 times over the past five years.

Dr. Marshall’s research team is focused primarily on screening and characterizing various vaccine formulations that incorporate immunostimulatory CpG DNA and determining their suitability for clinical development in the fields of hepatitis and allergy. He and his group are particularly interested in exploring the effects of these vaccines on humoral and cell-mediated immunity with particular emphasis on T cell responses in mouse, monkey, and human in vitro and in vivo systems. They are also currently engaged in exploring the immunobiology of CpG DNA and TLR9 interaction, in regard to target cells, species specificity, direct and downstream immune effects, and counter-regulation with other members of the TLR family.

The *Journal of Leukocyte Biology* also recognizes and honors the five runner-up highly cited original research papers:

Paper #2 with 71 citations: “Comparative analysis of IRF and IFN- $\alpha$  expression in human plasmacytoid and monocyte-derived dendritic cells” by Alexander Izaguirre, Betsy J. Barnes, Sheela Amrute, Wen-Shuz Yeow, Nicholas Megjugorac, Jihong Dai, Di Feng, Eugene Chung, Paula M. Pitha, and Patricia Fitzgerald-Bocarsly. (*J. Leukoc. Biol.* 74, 1125–1138, 2003);

Paper #3 with 70 citations: “Toll-like receptor 9 mediates CpG-DNA signaling” by Tsung-Hsien Chuang, Jongdae Lee,

Lois Kline, John C. Mathison, and Richard J. Ulevitch. (*J. Leukoc. Biol.* 71, 538–544, 2002);

Paper #4 with 67 citations: “Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide” by Mayda Gursel, Daniela Verthelyi, Ihsan Gursel, Ken J. Ishii, and Dennis M. Klinman. (*J. Leukoc. Biol.* 71, 813–820, 2002);

Paper #5 with 65 citations: “Many chemokines including CCL20/MIP-3 $\alpha$  display antimicrobial activity” by De Yang, Qian Chen, David M. Hoover, Patricia Staley, Kenneth D. Tucker, Jacek Lubkowski, and Joost J. Oppenheim. (*J. Leukoc. Biol.* 74, 448–455, 2003);

Paper #6 with 51 citations: “Differential expression of FIZZ1 and Ym1 in alternatively vs. classically activated macrophages” by Geert Raes, Patrick De Baetselier, Wim Noel, Alain Beschin, Frank Brombacher, and Gholamreza Hassan-zadeh Gh. (*J. Leukoc. Biol.* 71, 597–602, 2002);

The winner of the 2007 Dolph Adams Award for the most highly cited review article is Michael Kracht from the Institute of Pharmacology, Medical School Hannover, Hannover, Germany. “Multiple control of interleukin-8 gene expression” by Elke Hoffmann, Oliver Dittrich-Breiholz, Helmut Holtmann, and Michael Kracht (*J. Leukoc. Biol.* 72, 847–855, 2002) has been cited 192 times in the past five years.

Dr. Kracht’s laboratory has had a long-standing interest in the details of inflammatory signal transduction and gene expression, and he has specifically chosen interleukin-8 (IL-8) for in-depth evaluation due to the variety of pathways leading to its production as well as the remarkably diverse nature of the different cells from which it can be produced. Dr. Kracht has noted that, around the time that this award-winning review was accepted, he and his laboratory group had just developed a customized DNA microarray to track the expression of other genes (in addition to IL-8) for the purpose of obtaining a broader view of quantitative and qualitative aspects of inflammatory gene regulation. Together with co-author Oliver Dittrich-Breiholz, Dr. Kracht established a small but efficient microarray facility which has led to productive collaborations with other research groups interested in inflammation (<http://www.mh-hannover.de/forschung/sfb566/microarray/>). Among other co-authors, Elke Hoffmann remained with his group until the summer of 2007, and provided the laboratory group with ChIP-Chip experimental data for evaluation of gene expression at a genome-wide level. Helmut Holtmann has moved from the Department of Pharmacology to the Department of Biochemistry of the Hannover Medical School where he continues his successful work on posttranscriptional mechanisms of inflammatory gene regulation; he and Dr. Kracht continue to com-

---

doi: 10.1189/jlb.1107999

municate and publish papers together. Dr. Kracht has recently moved from Hannover Medical School to become head of the Department of Pharmacology of the Medical Faculty of the Justus-Liebig-University Giessen. His laboratory is continuing with its studies on IL-8, including a set of experiments that appear to suggest that secreted IL-8 augments IL-1-induced gene responses, as well as an ongoing evaluations of AP-1 dimers and *egr1*, factors that regulate IL-8 gene expression.

In recognition, the *Journal of Leukocyte Biology* honors the five runner-up highly-cited review articles:

Review #2 with 180 citations: “Interferon- $\gamma$ : An overview of signals, mechanisms and functions” by Kate Schroder, Paul J. Hertzog, Timothy Ravasi, and David A. Hume. (*J. Leukoc. Biol.* 75, 163–189, 2004);

Review #3 with 135 citations: “How we detect microbes and respond to them: the Toll-like receptors and their transducers” by B. Beutler, K. Hoebe, X. Du, and R. J. Ulevitch. (*J. Leukoc. Biol.* 74, 479–485, 2003);

Review #4 with 123 citations: “Interleukin-18” by J. Alastair Gracie, Susan E. Robertson, and Iain B. McInnes. (*J. Leukoc. Biol.* 73, 213–224, 2003);

Overview #5 with 119 citations: “Cathelicidins, multifunctional peptides of the innate immunity” by Margherita Zanetti (*J. Leukoc. Biol.* 75, 39–48, 2004);

Review tied for #6 with 88 citations: “Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases” by Mark T. Quinn and Katherine A. Gauss. (*J. Leukoc. Biol.* 76, 760–781, 2004);

Review tied for #6 with 88 citations: “Endogenous ligands of Toll-like receptors” by Min-Fu Tsan and Baochong Gao. (*J. Leukoc. Biol.* 76, 514–519, 2004).

The *Journal of Leukocyte Biology* continued to improve its standing in 2007. The Citation Index has remained about the same at 4.572 for the past year and the journal’s ranking remained 10th among peer-reviewed hematology journals and was 12th in the immunology group. Despite an ever-increasing number of journals, we continue to fulfill a need for authors interested in publishing their work on the cell biology of host defense. We continue to invite timely reviews of relevant topics and overviews from plenary and symposium speakers at relevant meetings. Reviews are cited about three times as often and overviews twice as often as unsolicited papers. The number of submitted papers and reviews will exceed 750 this year. Although our acceptance rate has tightened from 38% to 35%, the number of papers published in 2007 increased to 355 in 3210 pages. Fortunately, the cost of this increase is covered by page charges; and *JLB* revenue from color charges, advertising, and copyright royalties will all exceed the budget estimates for



Michael Kracht, corresponding author of the 2007 Dolph Adams prize for most-highly cited review, is head of the Pharmacology department of the medical faculty of the Justus-Liebig-University Giessen and studies the regulated expression of IL-8 and related inflammatory responses.

2007. *JLB* is in good economic shape. Also, the duration of our review period has improved—by sending automatic reminders to our reviewers, the average number of days from submission to final decision was reduced from 68 to 51.

In June of 2006 under the leadership of Associate Editor, Helene Rosenberg, we initiated monthly publication of interviews with the corresponding authors of papers selected as representing “Pivotal Advances.” In an effort to supplement the rather impersonal scientific reports in *JLB*, we have chosen to reveal more about the research programs, personal attitudes, and scientific goals of contributing authors. We hope you enjoy reading these interviews and that they increase your appreciation of your fellow scientists and their work.

We are also adding a new *JLB* category entitled “Translational and Clinical Research.” This is aimed at improving our coverage of research on the role of leukocytes in animal models of disease states and clinical conditions. Appropriate section editors are being recruited to cover these topics. We greatly appreciate your feedback by e-mail and letter and welcome suggestions for the further improvement of *JLB*.

Sincerely,  
Helene F. Rosenberg, Associate Editor  
Joost J. Oppenheim, Editor-in-Chief